This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

CardioNet, Rexahn Pharma: Volume Movers

NEW YORK ( TheStreet) -- CardioNet (BEAT - Get Report) was one of several stocks moving on above-average volume Monday as concerns over national healthcare reimbursements for the medical technology company's services drove shares lower.

CardioNet said the Centers for Medicare and Medicaid Services (CMS) proposed that that the technical component of mobile cardiovascular telemetry remains carrier-priced for calendar year 2011. The CMS will give it final rule by Nov. 1 for implementation on Jan. 1, 2011, and if adopted means that local Medicare contractors will decide on reimbursement amounts.

"Given our efforts to obtain a national reimbursement rate for CardioNet's MCOTTM technology, we are disappointed in CMS' Proposed Rule," CardioNet CEO Joe Capper said in a statement. "We will work diligently during the public comments period to request that CMS change its recommendation to one that is more beneficial to Medicare recipients who depend on MCOTTM."

CardioNet shares were down 76 cents, or 10.6%, to $6.42. Volume topped 938,000 shares, compared to the 50-day average daily volume of 406,000, according to the Nasdaq.

Elsewhere, Rexahn Pharmaceuticals (RNN) dropped by 17 cents, or 9.9%, to $1.55 after the drug company said it has raised $10 million through a registered direct offering. Institutional investors bought units consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock at a purchase price of $1.50.

Rexahn said net proceeds of approximately $9.45 million will be used for further development of the company's lead clinical programs, including the funding of Rexahn's Phase II clinical study program of serdaxin, zoraxel and archexin.

Rexahn's volume topped 832,000 shares, compared to the three-month average daily volume of 2.13 million, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BEAT $10.68 1.91%
RNN $0.78 0.62%
AAPL $128.54 -0.63%
FB $80.90 1.63%
GOOG $573.37 -0.05%

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs